All In Biotech

Drug Trial Radar · NCT03324113

Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors

A Phase I Study to Evaluate Safety and Pharmacokinetics of SAR408701 Administered Intravenously as Monotherapy in Japanese Patients With Advanced Malignant Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

34

Actual

Start

Oct 17, 2017

Primary completion

Nov 18, 2022

Study completion Dec 26, 2022

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Oct 27, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Primary Objective: * To evaluate tolerability and safety of SAR408701 when administered as a single agent according to the investigational medicinal product (IMP) related dose limiting toxicities (DLTs) to determine the recommended dose (RD) of SAR408701 in Japanese patients with advanced malignant solid tumors. Secondary Objectives: * To characterize the overall safety profile of SAR408701 monotherapy. * To characterize the pharmacokinetic (PK) profile of SAR408701 and its metabolites. * To evaluate the pharmacodynamic (PDy) effect of SAR408701 on levels of circulating carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) for main dose escalation part. * To assess preliminary efficacy according to Response Evaluation Criteria in Solid Tumor (RECIST) 1.1 criteria and other indicators of antitumor activity. * To assess the potential immunogenicity of SAR408701.

Conditions

  • Neoplasm Malignant

Interventions

  • SAR408701Drug

    Pharmaceutical form: solution for infusion Route of administration: intravenous

  • dexamethasoneDrug

    Pharmaceutical form: solution for eye drop Route of administration: eye drop

  • naphazolineDrug

    Pharmaceutical form: solution for eye drop Route of administration: eye drop

  • diphenhydramineDrug

    Pharmaceutical form: tablet Route of administration: oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. IMP-related dose limiting toxicities (DLT)Time frame: 4 weeks, Dose escalation q3w part: 3 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Investigational Site Number : 3920002

    Nagoya, Aichi-ken, Japan

  • Investigational Site Number : 3920003

    Kashiwa-shi, Chiba, Japan

  • Investigational Site Number : 3920001

    Sunto-gun, Shizuoka, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.